Summit Therapeutics Inc. (NasdaqGM: SMMT)
Health Care · Biotechnology · US
$17.17
-4.35% today · -19.5% 1Y
Summit Therapeutics Inc. (NasdaqGM: SMMT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $14.36B and employs 265 people.
Over the last twelve months the share price has lost 19.5%, trading between 12.07 and 29.23.
Tweenvest scores Summit Therapeutics Inc. across four factors: quality 37/100, value 71/100. Its strongest factor is value.
SMMT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $14.36B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.12
- Dividend yield
- —
- Beta (5Y)
- -1.52
- 52-week high
- $29.23
- 52-week low
- $12.07
- Avg volume (3M)
- —
- Shares outstanding
- 799.73M
- Employees
- 265
- Next earnings
- —
About Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
- ISIN
- US86627T1088
- Founded
- 2003
- Listed since
- Mar 5, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ascendis Pharma A/SNasdaqGS: ASND | $15.00B | $222.69 | -2.50% |
| Swedish Orphan Biovitrum AB (publ)OM: SOBI | $14.83B | Skr422.40 | -1.26% |
| Neurocrine Biosciences, Inc.NasdaqGS: NBIX | $14.58B | $141.25 | -1.55% |
| Exelixis, Inc.NasdaqGS: EXEL | $14.48B | $59.02 | +0.99% |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.SEHK: 6990 | $14.27B | HK$468.60 | -1.97% |
| ALTEOGEN Inc.KOSDAQ: A196170 | $13.42B | ₩259,500.00 | +3.80% |
| BridgeBio Pharma, Inc.NasdaqGS: BBIO | $13.00B | $65.04 | -2.20% |
| Halozyme Therapeutics, Inc.NasdaqGS: HALO | $12.57B | $109.84 | -0.86% |
Figures last refreshed Oct 4, 2026.